Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis

Psoriasis and psoriatic arthritis are chronic inflammatory diseases affecting the skin and joints, respectively. Psoriasis and psoriatic arthritis are associated with a high comorbidity burden as well as negative impact on quality of life. Impact on health-related quality of life is optimized when b...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2022-12, Vol.67, p.102292-102292, Article 102292
Main Authors: Lin, Christine P., Merola, Joseph F., Wallace, Elizabeth B.
Format: Article
Language:English
Subjects:
Adult
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - epidemiology
Biological Products - therapeutic use
Comorbidity
Humans
Psoriasis - drug therapy
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis and psoriatic arthritis are chronic inflammatory diseases affecting the skin and joints, respectively. Psoriasis and psoriatic arthritis are associated with a high comorbidity burden as well as negative impact on quality of life. Impact on health-related quality of life is optimized when both skin and joint manifestations are effectively treated. The identification of key cytokines involved in disease pathogenesis has led to the development of several therapeutic options for psoriatic disease. When selecting a therapy, it is important to consider disease severity, psoriasis disease subtypes or domains of psoriatic arthritis, comorbidities, patient preference for treatment, among other factors. This review summarizes current biologic and small molecule treatment options as well as emerging therapies for moderate-to-severe adult plaque psoriasis and psoriatic arthritis.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2022.102292